Notice of Results

RNS Number : 9632H

Proteome Sciences PLC

30 March 2020

 

  30 March 2020

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Notice of Results

Further to our announced intention to publish our audited 2019 full year results on 31 March 2020, the Board wishes to notify shareholders that this will now be postponed until Tuesday April 14^th. This follows advice and additional guidance on financial reporting from the Financial Conduct Authority and the Financial Reporting Council in light of the ongoing coronavirus pandemic. Accordingly, the date of the Annual General Meeting ("AGM") will also be revised. We will provide further notification regarding the date of the AGM as soon as we can be certain of our ability to provide a safe environment for all wishing to attend.

Despite the ongoing restrictions on non-essential travel and gatherings, both our UK and German organisations are able to function normally, and we do not expect the coronavirus pandemic to have a material effect on our first quarter revenues. The current COVID-19 crisis underlines the necessity for increased testing and vaccine development in the rapidly changing medical environment. Several scientific articles are appearing where researchers are using TMT® proteomics to look at how the virus interacts with the human cellular proteome, which plays to our core strength.

For further information please contact:

Proteome Sciences plc
Dr Ian Pike, Interim Chief Executive Officer	Tel: [phone]
Richard Dennis, Chief Commercial Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter	Tel: [phone]

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

 

END

 

 

NORFFFFFVAIAFII